Advances in opioid antagonist treatment for opioid addiction.
UCLA Department of Psychiatry and Biobehavioral Sciences, UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA. lwalter@ucla.edu
Walter
W
Ling
Larissa
L
Mooney
Li-Tzy
LT
Wu
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001521:Behavior Therapy; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018755:GABA Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D055118:Medication Adherence; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D018755:GABA Agonists; D009292:Narcotic Antagonists; D009271:Naltrexone